The Evolution of NSCLC Treatment Through Bispecific Antibodies

ha aggiunto una foto Altre informazioni

2025-05-01 13:47:37 -

Non-Small Cell Lung Cancer (NSCLC) continues to be the most common form of lung cancer, responsible for approximately 85% of all cases. Despite advancements with targeted therapies and immuno-oncology, long-term outcomes remain suboptimal for many patients. A new class of therapeutics—bispecific antibodies—is revolutionizing the landscape by targeting two distinct cancer pathways at...

0 Commenti 0 condivisioni 761 Views 0 Anteprima